Erasca, Inc. ( ERAS ) is a developmental biotech operating almost entirely in the space of developing novel targeted therapies against the RAS/MAP kinase pathway in solid tumor oncology. Having fallen over 50% sinceI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls o ...

Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Erasca will also present potential first-in-class examples of direct SMP complex inhibitors, representing a new approach to block the RAS/MAPK pathway SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers ...

Financial Performance - The company has incurred significant operating losses of $161.7 million and $125.0 million for the years ended December 31, 2024 and 2023, respectively, with an accumulated deficit of $767.7 million as of December 31, 2024[295]. - The company has not generated any revenue since its inception in 2018 and does not have any products approved for sale[295]. - The company expects to continue incurring significant losses for the foreseeable future, with anticipated increases in expenses related to ongoing clinical trials and regulatory approvals[295]. - The company believes its existing cash, cash equivalents, and marketable securities will fund operations into the second half of 2027, but may need additional capital sooner than planned[299]. - The company has entered into an Open Market Sale Agreement allowing for the sale of up to $200 million in common stock, with $21.9 million sold as of December 31, 2024[299]. - The company has incurred substantial losses and does not expect to achieve profitability in the near future, which may limit the use of its NOL carryforwards[429]. Clinical Development and Regulatory Challenges - The ongoing SEACRAFT-2 Phase 3 clinical trial for naporafenib is the only advanced program, while other product candidates remain in preclinical or discovery stages[294]. - The company may face challenges in obtaining regulatory approvals and successfully commercializing its product candidates, which could materially harm its business[306]. - Clinical and preclinical development is lengthy and expensive, with a high historical failure rate for product candidates in the industry[312]. - The company may face delays in clinical trials due to various factors, including regulatory approvals, patient enrollment challenges, and trial protocol deviations[316]. - Any safety concerns observed in clinical trials could limit the prospects for regulatory approval of the company's product candidates, adversely affecting its business and financial condition[314]. - The company must conduct extensive clinical studies to demonstrate the safety, purity, potency, and efficacy of its product candidates before obtaining marketing approval[315]. - The regulatory approval processes are lengthy and unpredictable, with a small percentage of drugs successfully completing the FDA approval process[332]. - The company plans to conduct multiple clinical trials for various product candidates in parallel, which may strain its limited resources and management focus[336]. - The company may need to conduct additional clinical trials or studies post-approval, which could delay commercialization[335]. - The company is conducting clinical trials outside the United States, which may face acceptance issues from the FDA, potentially delaying development plans and harming the business[342]. Intellectual Property and Patent Risks - The company’s success is heavily dependent on obtaining and maintaining patent protection for its product candidates, which is complex and costly[435]. - The patent prosecution process is time-consuming, and failure to identify patentable aspects could jeopardize the company's ability to protect its innovations[437]. - The company may face challenges in enforcing its intellectual property rights in foreign jurisdictions, which could diminish its competitive position[444]. - The company may face claims challenging the inventorship of its patents, which could result in loss of valuable intellectual property rights[461]. - The company partially depends on intellectual property licensed from third parties, and failure to comply with obligations could result in loss of significant rights[478]. - The company does not have complete control over the maintenance and prosecution of its in-licensed patents, which could affect commercialization efforts[479]. Market and Competitive Landscape - The commercial success of product candidates will depend on market acceptance among physicians, patients, and healthcare payors, influenced by clinical efficacy and safety[379]. - The company faces competition for access to manufacturing facilities, particularly due to the high potency of its product candidates[367]. - Competition in the oncology sector is intense, with numerous companies developing therapies targeting similar indications, which may affect the commercial potential of the company's products[388]. - The company faces significant competition for qualified personnel, which may impede its ability to achieve development objectives and implement its business strategy[402]. - The company currently lacks a marketing and sales organization and may need to invest significant resources to develop these capabilities for product commercialization[395]. Financial and Operational Risks - The company may need to rely on additional financing to achieve its business objectives, which could lead to dilution of stockholder interests[303]. - The company may face significant negative consequences if undesirable side effects are identified post-approval, impacting market acceptance[326]. - The company may incur substantial liabilities from product liability lawsuits, which could limit the commercialization of its products[413]. - The unpredictability of operating results makes it difficult for the company to meet analysts' expectations, potentially leading to a decline in stock price[400]. - The company may face significant uninsured liabilities due to the high costs and limitations of its insurance policies, which could adversely affect its financial position[416]. Compliance and Regulatory Environment - The company is subject to various healthcare laws and regulations that could increase compliance costs and expose it to significant penalties if violated[404]. - The company is subject to regulatory reporting obligations regarding adverse medical events, with potential sanctions for non-compliance that could materially harm its business[417]. - Compliance with Good Clinical Practice (GCP) and current Good Manufacturing Practice (cGMP) regulations is essential; non-compliance may require repeating clinical trials[361]. - The company may engage in strategic transactions, such as acquisitions or partnerships, which could impact liquidity and increase expenses[428]. Data Privacy and Cybersecurity - Cybersecurity risks pose a threat to the company's information technology systems, which could result in material disruptions and significant financial penalties[418]. - The company is subject to various federal and state data privacy laws, including HIPAA and the California Consumer Privacy Act (CCPA), which may impose additional compliance burdens[489]. - Evolving legal obligations regarding data privacy and cybersecurity may create inconsistencies and conflicts, potentially leading to increased liability and reputational damage[492].

Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 Ongoing Phase 3 SEACRAFT-2 registrational trial progressing well with Stage 1 randomized data expected in H2 2025 Robust balance sheet with cash, cash equivalents, and marketable securities of $440 million as of December 31, 2024 is expected to fund operations into H2 2027 SAN DIEGO, March 20 ...

Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 Ongoing Phase 3 SEACRAFT-2 registrational trial progressing well with Stage 1 randomized data expected in H2 2025 Robust balance sheet with cash, cash equivalents, and marketable securities of $440 million as of December 31, 2024 is expected to fund operations into H2 2027 SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncol ...

SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Securities SMID Cap Biotech Conference being held at the Lotte New York Palace in New York, New York. Management will participate in a fireside chat on Thursday, February 6, 2025, at 9:30 am Eastern Time and will a ...

Erasca (NASDAQ: ERAS ) is a precision oncology company, which means it focuses on therapies that target very specific cancer-related mutations. In particular, the main pathways it uses are the RAS/MAPK pathways. ERAS has a relatively late-stage pipeline with Naporafenib, whichMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, ...

Erasca, Inc. (ERAS) has been beaten down lately with too much selling pressure. While the stock has lost 25.4% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that ...

Erasca, Inc. (ERAS) has been beaten down lately with too much selling pressure. While the stock has lost 27.2% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that ...

Core Viewpoint - Erasca, Inc. (ERAS) is experiencing significant selling pressure, having declined 24.1% over the past four weeks, but is now positioned for a potential trend reversal as it is in oversold territory and analysts expect better earnings than previously predicted [1] Group 1: Stock Performance and Technical Indicators - The stock's Relative Strength Index (RSI) reading is at 20.63, indicating it is oversold and suggesting a potential reversal in trend [5] - A stock is generally considered oversold when its RSI falls below 30, which helps investors identify entry opportunities for potential rebounds [2][3] Group 2: Earnings Estimates and Analyst Consensus - There is strong agreement among sell-side analysts in raising earnings estimates for ERAS, with a 1% increase in the consensus EPS estimate over the last 30 days [6] - An upward trend in earnings estimate revisions typically correlates with price appreciation in the near term [6] Group 3: Zacks Rank and Investment Potential - ERAS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [7]